Peter Neumann, ScD, Dan Ollendorf, PhD
The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center is pleased to announce that the Institute for Clinical and Economic Review (ICER) will begin to use CEVR’s Cost-Effectiveness Analysis (CEA) Registry to help evaluate drugs and other medical interventions.
ICER is an independent, nonprofit organization that assesses the value of pharmaceuticals and other technologies. The organization conducts clinical and economic reviews, which feature cost-effectiveness analyses to help determine how each treatment should be priced to reflect improved patient outcomes. ICER’s reviews also reflect upon the interventions’ short-term budget impact, as well as contextual considerations important to patients.
CEVR’s CEA Registry catalogs detailed information from more than 7,000 cost-effectiveness analyses (CEA), including 18,000 incremental cost-effectiveness ratios, and 27,000 utility weights.
Use of the Registry’s data confers multiple potential benefits for ICER’s reviews:
- As an efficient way to see how others have modeled a disease: Knowing how to structure a model – for example, what health states and transition pathways to include – is key to developing a credible analysis. Being able to quickly identify and review past efforts may help ICER’s collaborators more efficiently prototype the most clinically appropriate models.
- As a data source: ICER will gain access to a single source for health-state utility estimates, cost estimates, and other modeling assumptions. By supplementing ICER’s own literature reviews and stakeholder engagement, the Registry will decrease the risk that an ICER model excludes an important piece of information.
- As a recruitment tool: ICER can use the Registry to identify potential collaborators who have worked in a particular disease or intervention area.
“The goal of the CEA Registry is to help decision makers understand society’s best opportunities for improving health given resource constraints,” notes CEVR’s Director, Peter Neumann. “We are very pleased to support ICER’s vital efforts to use cost-effectiveness information to rigorously evaluate health care interventions.”